These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 14655481)

  • 21. Angiotensin receptor blockers in diabetic nephropathy.
    Price DA; Hollenberg NK
    Curr Diab Rep; 2001 Dec; 1(3):267-74. PubMed ID: 12643209
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Current treatment of diabetic nephropathy in patients with type II diabetes mellitus. Most recent progress].
    de Alvaro F
    Nefrologia; 2001; 21 Suppl 3():76-82. PubMed ID: 11642211
    [No Abstract]   [Full Text] [Related]  

  • 23. Is Chronic Dialysis the Right Hard Renal End Point To Evaluate Renoprotective Drug Effects?
    Weldegiorgis M; de Zeeuw D; Dwyer JP; Mol P; Heerspink HJL
    Clin J Am Soc Nephrol; 2017 Oct; 12(10):1595-1600. PubMed ID: 28923834
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations.
    Pohl MA; Blumenthal S; Cordonnier DJ; De Alvaro F; Deferrari G; Eisner G; Esmatjes E; Gilbert RE; Hunsicker LG; de Faria JB; Mangili R; Moore J; Reisin E; Ritz E; Schernthaner G; Spitalewitz S; Tindall H; Rodby RA; Lewis EJ
    J Am Soc Nephrol; 2005 Oct; 16(10):3027-37. PubMed ID: 16120823
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Irbesartan slows the development of diabetic nephropathy by up to 70% in hypertensive diabetic patients.
    Cardiovasc J S Afr; 2001; 12(4):242-3. PubMed ID: 11766619
    [No Abstract]   [Full Text] [Related]  

  • 26. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
    Lewis EJ; Hunsicker LG; Clarke WR; Berl T; Pohl MA; Lewis JB; Ritz E; Atkins RC; Rohde R; Raz I;
    N Engl J Med; 2001 Sep; 345(12):851-60. PubMed ID: 11565517
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
    Parving HH; Lehnert H; Bröchner-Mortensen J; Gomis R; Andersen S; Arner P;
    N Engl J Med; 2001 Sep; 345(12):870-8. PubMed ID: 11565519
    [TBL] [Abstract][Full Text] [Related]  

  • 28. What is the impact of PRIME on real-life diabetic nephropathy?
    Ruilope LM
    Int J Clin Pract; 2004 Mar; 58(3):268-76. PubMed ID: 15117095
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiotensin-receptor blockers, type 2 diabetes, and renoprotection.
    Ceriello A; Motz E
    N Engl J Med; 2002 Feb; 346(9):705-7. PubMed ID: 11873779
    [No Abstract]   [Full Text] [Related]  

  • 30. [Organ protection in hypertensive type 2 diabetic patients. Double chance with AT1 blockers].
    MMW Fortschr Med; 2000 Jan; 142(3):58-9. PubMed ID: 10726465
    [No Abstract]   [Full Text] [Related]  

  • 31. [Diabetic patient with hypertension takes A-I I blocker. Less likely dialysis].
    MMW Fortschr Med; 2002 Feb; 144(8):52. PubMed ID: 11910830
    [No Abstract]   [Full Text] [Related]  

  • 32. Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis.
    Palmer AJ; Valentine WJ; Ray JA
    Int J Clin Pract; 2007 Oct; 61(10):1626-33. PubMed ID: 17877649
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
    Parving HH; Lehnert H; Brøchner-Mortensen J; Gomis R; Andersen S; Arner P
    Ugeskr Laeger; 2001 Oct; 163(40):5519-24. PubMed ID: 11601118
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical and health economic implications of early treatment with irbesartan of patients with type 2 diabetes mellitus, hypertension and nephropathy].
    Palmer AJ; Roze S; Rodby RA; Valentine WJ; Ritz E; Lehnert H
    Dtsch Med Wochenschr; 2006 Aug; 131(31-32):1721-6. PubMed ID: 16868875
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Type 2 diabetic patient with kidney damage. Sartans banish dialysis risk].
    MMW Fortschr Med; 2004 Jul; 146(27-28):56. PubMed ID: 15526676
    [No Abstract]   [Full Text] [Related]  

  • 36. Effect of Irbesartan treatment on plasma and urinary markers of protein damage in patients with type 2 diabetes and microalbuminuria.
    Rabbani N; Adaikalakoteswari A; Rossing K; Rossing P; Tarnow L; Parving HH; Thornalley PJ
    Amino Acids; 2012 May; 42(5):1627-39. PubMed ID: 21384133
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcome studies in diabetic nephropathy.
    Mohanram A; Toto RD
    Semin Nephrol; 2003 May; 23(3):255-71. PubMed ID: 12838494
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Irbesartan prevents the progression of kidney disease or death in patients with type 2 diabetes and high blood pressure.
    Cardiovasc J S Afr; 2001; 12(4):240-1. PubMed ID: 11766617
    [No Abstract]   [Full Text] [Related]  

  • 39. [Milestone studies provide evidence: sartans have a nephroprotective effect. Evidence is clear].
    Bold KO
    MMW Fortschr Med; 2001 May; 143(22):12-3. PubMed ID: 11460392
    [No Abstract]   [Full Text] [Related]  

  • 40. Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria.
    Andersen S; Bröchner-Mortensen J; Parving HH;
    Diabetes Care; 2003 Dec; 26(12):3296-302. PubMed ID: 14633817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.